Regulatory bodies, including the FDA and the WHO, have stringent guidelines for vaccine approval. They require extensive safety and efficacy data from preclinical and clinical trials before a vaccine can be licensed. Continuous monitoring through pharmacovigilance programs ensures that any emerging safety issues are quickly addressed. These efforts maintain public trust in vaccination programs by ensuring that vaccines, including the acellular pertussis vaccine, meet high safety standards.
